Fukumura, Dai
Kloepper, Jonas
Amoozgar, Zohreh
Duda, Dan G.
Jain, Rakesh K.
Article History
First Online: 6 March 2018
Competing interests
: D.G.D. has received consultancy fees from Bayer and research funding from Bayer, Bristol-Myers Squibb, Exelixis, Leap, and Merrimack. R.K.J. has received consultancy fees from Merck, Ophthotech, Pfizer, SPARC, and SynDevRx; owns equity in Enlight, Ophthotech, SynDevRx, and XTuit; and serves on the board of directors of XTuit and the boards of trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund. D.F., Z.A., and J.K. do not have any conflicts of interest to declare.
Free to read: This content has been made available to all.